Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
•
0 j'aime•180 vues
Recommandé
Recommandé
Contenu connexe
Tendances
Tendances (20)
En vedette
Similaire à Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
Similaire à Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture (19)
Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
- 1. Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture Report Details: Published:November 2012 No. of Pages: 270 Price: Single User License – US$2500 Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture Summary GlobalData’s new report, “Japan In Vitro Diagnostics Market Outlook to 2018- Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture” provides key market data on the Japan In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on company financials and pipeline products, wherever available. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. Scope - Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. - Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2004 to 2011, forecast forward for 7 years to 2018.
- 2. - 2011 company shares and distribution shares data for each of the seven market categories. - Global corporate-level profiles of key companies operating within the Japan In Vitro Diagnosticsmarket. - Key players covered include F. Hoffmann-La Roche Ltd., Siemens Healthcare, Abbott Laboratories, Sysmex Corporation, Ortho-Clinical Diagnostics Inc., Beckman Coulter, Inc. and others. Reasons to buy - Develop business strategies by identifying the key market categories and segments poised for strong growth. - Develop market-entry and market expansion strategies. - Design competition strategies by identifying who-stands-where in the Japan In Vitro Diagnostics competitive landscape. - Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future. - What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize. Get your copy of this report @ http://www.reportsnreports.com/reports/210642-japan-in-vitro-diagnostics-market-outlook-to-2018-clinical- chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and- microbiology-culture.html Major points covered in Table of Contents of this report include 1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 9 1.2 List of Figures 14 2 Introduction 17 2.1 What is This Report About? 17 3 In Vitro Diagnostics In Japan 18 3.1 In Vitro Diagnostics, Market Segmentation 18 3.2 In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 19 3.3 In Vitro Diagnostics Market, Japan, Revenue Mix ($m), 2011 21 3.4 In Vitro Diagnostics Market, Japan, Category Contribution (%), 2011 22 3.5 In Vitro Diagnostics, Japan, Company Share (2010-2011) 29 4 Clinical Chemistry In Japan 31 4.1 Clinical Chemistry, Market Segmentation 31 4.2 Clinical Chemistry Market, Japan, Revenue Mix ($m), 2011 32 4.3 Clinical Chemistry Market, Japan, Segment Contribution (%), 2011 33 4.4 Clinical Chemistry Overall Revenue, (2004-2018) 34 4.4.1 Clinical Chemisty Analyzers, Revenue (2004-2018) 38 4.4.2 Urine Analysis, Revenue (2004-2018) 42
- 3. 4.5 Clinical Chemistry Distribution Share (2010-2011) 44 4.6 Clinical Chemistry, Japan, Company Share (2010-2011) 45 5 Genetic Testing In Japan 47 5.1 Genetic Testing, Market Segmentation 47 5.2 Genetic Testing Market, Japan, Revenue Mix ($m), 2011 48 5.3 Genetic Testing Market, Japan, Segment Contribution (%), 2011 49 5.4 Genetic Testing Overall Revenue, (2004-2018) 50 5.5 Genetic Testing Distribution Share (2010-2011) 54 5.6 Genetic Testing, Japan, Company Share (2010-2011) 55 6 Haematology In Japan 56 6.1 Haematology Market, Market Segmentation 56 6.2 Haematology Market, Japan, Revenue Mix ($m), 2011 57 6.3 Haematology Market, Japan, Segment Contribution (%), 2011 58 6.4 Haematology Overall Revenue, (2004-2018) 59 6.4.1 Haematology Reagents, Revenue (2004-2018) 63 6.4.2 Immunohaematology, Revenue (2004-2018) 67 6.4.3 Haemostasis, Revenue (2004-2018) 71 6.4.4 Haematology Rapid Tests, Revenue (2004-2018) 75 6.4.5 Haematology Cell Counters, Revenue (2004-2018) 79 6.5 Haematology Distribution Share (2010-2011) 83 6.6 Haematology, Japan, Company Share (2010-2011) 84 7 Histology And Cytology In Japan 86 7.1 Histology and Cytology Market, Market Segmentation 86 7.2 Histology And Cytology Market, Japan, Revenue Mix ($m), 2011 87 7.3 Histology And Cytology Market, Japan, Segment Contribution (%), 2011 88 7.4 Histology And Cytology Overall Revenue, (2004-2018) 89 7.5 Histology And Cytology Distribution Share (2010-2011) 93 7.6 Histology And Cytology, Japan, Company Share (2010-2011) 94 8 Immuno Chemistry In Japan 96 8.1 Immuno Chemistry Market, Japan, Revenue Mix ($m), 2011 96 8.2 Immuno Chemistry Market, Japan, Segment Contribution (%), 2011 97 8.3 Immuno Chemistry Overall Revenue, (2004-2018) 99 8.3.1 Disease Specific Immunochemistry, Revenue (2004-2018) 103 8.3.2 Drugs of Abuse / Toxicology, Revenue (2004-2018) 107 8.3.3 Endocrinology Tests, Revenue (2004-2018) 111 8.3.4 Immunochemistry Rapid Tests, Revenue (2004-2018) 115 8.3.5 Therapeutic Drug Monitoring, Revenue (2004-2018) 119 8.3.6 Immunochemistry Analyzers, Revenue (2004-2018) 123 8.4 Immuno Chemistry Distribution Share (2010-2011) 127 8.5 Immuno Chemistry, Japan, Company Share (2010-2011) 128 9 Infectious Immunology In Japan 130 9.1 Infectious Immunology, Market Segmentation 130
- 4. 9.2 Infectious Immunology Market, Japan, Revenue Mix ($m), 2011 131 9.3 Infectious Immunology Market, Japan, Segment Contribution (%), 2011 132 9.4 Infectious Immunology Overall Revenue, (2004-2018) 133 9.4.1 Infectious Immunology Rapid Tests, Revenue (2004-2018) 137 9.5 Infectious Immunology Distribution Share (2010-2011) 141 9.6 Infectious Immunology, Japan, Company Share (2010-2011) 142 10 Microbiology Culture In Japan 144 10.1 Microbiology Culture, Market Segmentation 144 10.2 Microbiology Culture Market, Japan, Revenue Mix ($m), 2011 145 10.3 Microbiology Culture Market, Japan, Segment Contribution (%), 2011 146 10.4 Microbiology Culture Overall Revenue, (2004-2018) 147 10.4.1 Microbiology Analyzers, Revenue (2004-2018) 151 10.5 Microbiology Culture Distribution Share (2010-2011) 155 10.6 Microbiology Culture, Japan, Company Share (2010-2011) 156 11 Overview of Key Companies in Japan In Vitro Diagnostics Market 158 11.1 F. Hoffmann-La Roche Ltd. 158 11.1.1 Company Overview 158 11.1.2 Share in the Japan In Vitro Diagnostics Market 158 11.2 Siemens Healthcare 159 11.2.1 Company Overview 159 11.2.2 Share in the Japan In Vitro Diagnostics Market 159 11.3 Abbott Laboratories 160 11.3.1 Company Overview 160 11.3.2 Share in the Japan In Vitro Diagnostics Market 160 11.4 Sysmex Corporation 161 11.4.1 Company Overview 161 11.4.2 Share in the Japan In Vitro Diagnostics Market 161 11.5 Ortho-Clinical Diagnostics Inc. 162 11.5.1 Company Overview 162 11.5.2 Share in the Japan In Vitro Diagnostics Market 162 11.6 Beckman Coulter, Inc. 163 11.6.1 Company Overview 163 11.6.2 Share in the Japan In Vitro Diagnostics Market 163 11.7 Eiken Chemical Co.,Ltd. 164 11.7.1 Company Overview 164 11.8 Becton, Dickinson and Company 164 11.8.1 Company Overview 164 11.9 Bio-Rad Laboratories, Inc. 165 11.9.1 Company Overview 165 11.10 bioMerieux S.A. 165 11.10.1 Company Overview 165 11.11 Nihon Kohden Corporation 166
- 5. 11.11.1 Company Overview 166 11.12 Alere Inc. 166 11.12.1 Company Overview 166 11.13 DiaSorin S.p.A 167 11.13.1 Company Overview 167 11.14 Olympus Corporation 167 11.14.1 Company Overview 167 11.15 Horiba, Ltd. 168 11.15.1 Company Overview 168 11.16 Tosoh Corporation 168 11.16.1 Company Overview 168 11.17 Qiagen N.V. 169 11.17.1 Company Overview 169 11.18 Gen-Probe Incorporated 169 11.18.1 Company Overview 169 11.19 Mindray Medical International Limited 170 11.19.1 Company Overview 170 11.20 PerkinElmer, Inc. 170 11.20.1 Company Overview 170 11.21 Danaher Corporation 171 11.21.1 Company Overview 171 11.22 Grifols, S.A. 171 11.22.1 Company Overview 171 11.23 Diagnostica Stago, Inc. 172 11.23.1 Company Overview 172 11.24 Life Technologies Corporation 172 11.24.1 Company Overview 172 12 In Vitro Diagnostics Market Pipeline Products 173 12.1 Clinical Chemisty Market Pipeline Products 173 12.2 Immuno Chemistry Market Pipeline Products 176 12.3 Haematology Market Pipeline Products 185 12.4 Infectious Immunology Market Pipeline Products 187 12.5 Microbiology Culture Market Pipeline Products 194 12.6 Histology And Cytology Market Pipeline Products 195 12.7 Genetic Testing Market Pipeline Products 196 13 Financial Deals Landscape 201 13.1 Partnerships 201 13.1.1 bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 201 13.1.2 Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System 203 13.1.3 Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 204 13.1.4 BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology
- 6. Assays 205 13.1.5 Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 206 13.1.6 Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 207 13.1.7 Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 209 13.1.8 CML HealthCare Enters Into Agreement With MaRS Innovation 210 13.1.9 Akrivis Technologies Enters Into Co-Development Agreement With United States Biological 211 13.1.10 Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s Hospital For Mesothelioma Test 212 13.1.11 Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 213 13.1.12 GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 214 13.1.13 Dolomite Centre Enters Into Licensing Agreement With Japan Science and Technology Agency For Microdroplet Generation Technology 215 13.1.14 Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 216 13.1.15 Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 217 13.1.16 SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 218 13.1.17 Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic Systems 219 13.1.18 Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 220 13.1.19 MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 221 13.1.20 Guided Therapeutics Extends Licensing And Co-Development Agreement With Konica Minolta 222 13.1.21 NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus 223 13.1.22 Immuno-Biological Labs To Form Joint Venture With TransGenic 224 13.1.23 Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 225 13.1.24 Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test 226 13.1.25 One Lambda Enters Into Co-Marketing Agreement With CellTrend 227 13.1.26 Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 228 13.1.27 Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 229 13.1.28 Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 230 13.1.29 Pacific Biosciences Enters Into Co-Marketing Agreement With Tomy Digital Biology 231
- 7. 13.1.30 Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor Cell Technology 232 13.1.31 Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 233 13.1.32 Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 234 13.1.33 Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 235 13.1.34 Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology 236 13.1.35 Ezose Sciences Enters Into Co-Development Agreement With Hirosaki University For New Cancer Biomarkers 237 13.1.36 LipoScience Enters Into Licensing Agreement With Cleveland Clinic 238 13.1.37 GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System 239 13.1.38 Metabolon Enters Into Co-Development Agreement With Takeda Pharma 240 13.1.39 GE Healthcare Enters Into Research Agreement With Clino 241 13.1.40 NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 242 13.1.41 Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 243 13.1.42 Molecular Response Enters Into Co-Marketing Agreement With Transparent 244 13.1.43 Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure Chemical Industries 245 14 Recent Developments 246 14.1 Strategy And Business Planning 246 14.1.1 Oct 10, 2012: Eisai Group To Transform Product Creation Structure To Reflect Focus On Personalized Medicine 246 14.1.2 Jul 05, 2012: Shionogi Launches New European Headquarters In London 246 14.1.3 Apr 17, 2012: 3-D Matrix Establishes Wholly Owned New Subsidiary In France 247 14.1.4 Jan 19, 2012: Nihon Kohden Establishes Sales Subsidiary In Brazil 247 14.1.5 Nov 28, 2011: Shionogi To Announce Corporate Reorganization 247 14.2 Research And Development 248 14.2.1 Apr 23, 2012: Ezose And Hirosaki University To Collaborate In Glycomics Research To Find New Cancer Biomarkers 248 14.3 Government and Public Interest 249 14.3.1 Nov 08, 2012: New Portable Device Enables RNA Detection From Ultra-Small Sample In Only 20 Minutes 249 14.4 Product News 250 14.4.1 Aug 27, 2012: ARKRAY To Launch i-densy IS – 5320 Gene Analyzer 250 14.4.2 Jun 13, 2012: Fluidigm Introduces C1 Single-Cell AutoPrep System To Researchers At ISSCR 250 14.4.3 Feb 08, 2012: Alverix’s Partner BD Receives Japanese Regulatory Approval For BD Veritor System For Flu A+B 251 14.4.4 Jan 10, 2012: QIAGEN Receives Regulatory Approval In Japan For EGFR Companion
- 8. Diagnostic To Guide Cancer Treatments 252 14.4.5 Jan 10, 2012: QIAGEN Receives Regulatory Approval In Japan For EGFR Companion Diagnostic To Guide Cancer Treatments 252 14.4.6 Jul 22, 2011: Sysmex Launches Automated Blood Coagulation Analyzer CS-5100 253 14.4.7 May 10, 2011: Life Technologies Launches 3500 Dx Series Genetic Analyzer In Japan 253 14.4.8 May 10, 2011: Life Technologies Launches 7500 Fast Dx Real-Time PCR Instrument In Japan 254 15 Appendix 255 15.1 Definitions of Markets Covered in the Report 256 15.1.1 In Vitro Diagnostics 256 15.2 Research Methodology 267 15.3 Secondary Research 267 15.4 Primary Research 268 15.5 Models 268 15.6 Forecasts 269 15.7 Expert Panels 269 15.8 GlobalData Consulting 269 15.9 Currency Conversion 270 15.10 Contact Us 270 15.11 Disclaimer 270 1.1 List of Tables Table 1: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 20 Table 2: In Vitro Diagnostics Market, Japan, Category Contribution (%), 2011 22 Table 3: In Vitro Diagnostics Market, Japan, Cross-Category Analysis, 2004-2018 24 Table 4: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Historic, 2004-2011 26 Table 5: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 28 Table 6: In Vitro Diagnostics, Japan, Company Share by Revenue ($m), USD Constant, 2010- 2011 30 Table 7: Clinical Chemistry Market, Japan, Segment Contribution (%), 2011 33 Table 8: Clinical Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004- 2011 35 Table 9: Clinical Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011- 2018 37 Table 10: Clinical Chemisty Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 39 Table 11: Clinical Chemisty Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 41 Table 12: Urine Analysis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004- 2011 42
- 9. Table 13: Urine Analysis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011- 2018 43 Table 14: Clinical Chemistry, Japan, Distribution Share by Revenue ($m), USD Constant, 2010- 2011 44 Table 15: Clinical Chemistry, Japan, Company Share by Revenue ($m), USD Constant, 2010- 2011 46 Table 16: Genetic Testing Market, Japan, Segment Contribution (%), 2011 49 Table 17: Genetic Testing, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 51 Table 18: Genetic Testing, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011- 2018 53 Table 19: Genetic Testing, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 54 Table 20: Genetic Testing, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 55 Table 21: Haematology Market, Japan, Segment Contribution (%), 2011 58 Table 22: Haematology, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 60 Table 23: Haematology, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 62 Table 24: Haematology Reagents, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 64 Table 25: Haematology Reagents, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 66 Table 26: Immunohaematology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 68 Table 27: Immunohaematology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 70 Table 28: Haemostasis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004- 2011 72 Table 29: Haemostasis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011- 2018 74 Table 30: Haematology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 76 Table 31: Haematology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 78 Table 32: Haematology Cell Counters, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 80 Table 33: Haematology Cell Counters, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 82 Table 34: Haematology, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 83
- 10. Table 35: Haematology, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 85 Table 36: Histology And Cytology Market, Japan, Segment Contribution (%), 2011 88 Table 37: Histology And Cytology, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 90 Table 38: Histology And Cytology, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 92 Table 39: Histology And Cytology, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 93 Table 40: Histology And Cytology, Japan, Company Share by Revenue ($m), USD Constant, 2010-2011 95 Table 41: Immuno Chemistry Market, Japan, Segment Contribution (%), 2011 98 Table 42: Immuno Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004- 2011 100 Table 43: Immuno Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011- 2018 102 Table 44: Disease Specific Immunochemistry, Japan, Revenue ($m) USD Constant, by Sub- Segment, Historic, 2004-2011 104 Table 45: Disease Specific Immunochemistry, Japan, Revenue ($m) USD Constant, by Sub- Segment, Forecast, 2011-2018 106 Table 46: Drugs of Abuse / Toxicology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 108 Table 47: Drugs of Abuse / Toxicology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 110 Table 48: Endocrinology Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 112 Table 49: Endocrinology Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 114 Table 50: Immunochemistry Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 116 Table 51: Immunochemistry Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 118 Table 52: Therapeutic Drug Monitoring, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 120 Table 53: Therapeutic Drug Monitoring, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 122 Table 54: Immunochemistry Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 124 Table 55: Immunochemistry Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 126 Table 56: Immuno Chemistry, Japan, Distribution Share by Revenue ($m), USD Constant, 2010- 2011 127 Table 57: Immuno Chemistry, Japan, Company Share by Revenue ($m), USD Constant, 2010-
- 11. 2011 129 Table 58: Infectious Immunology Market, Japan, Segment Contribution (%), 2011 132 Table 59: Infectious Immunology, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 134 Table 60: Infectious Immunology, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 136 Table 61: Infectious Immunology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub- Segment, Historic, 2004-2011 138 Table 62: Infectious Immunology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub- Segment, Forecast, 2011-2018 140 Table 63: Infectious Immunology, Japan, Distribution Share by Revenue ($m), USD Constant, 2010-2011 141 Table 64: Infectious Immunology, Japan, Company Share by Revenue ($m), USD Constant, 2010- 2011 143 Table 65: Microbiology Culture Market, Japan, Segment Contribution (%), 2011 146 Table 66: Microbiology Culture, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004- 2011 148 Table 67: Microbiology Culture, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 150 Table 68: Microbiology Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 152 Table 69: Microbiology Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 154 Table 70: Microbiology Culture, Japan, Distribution Share by Revenue ($m), USD Constant, 2010- 2011 155 Table 71: Microbiology Culture, Japan, Company Share by Revenue ($m), USD Constant, 2010- 2011 157 Table 72: Clinical Chemisty Market Pipeline Products 173 Table 73: Immuno Chemistry Market Pipeline Products 176 Table 74: Haematology Market Pipeline Products 185 Table 75: Infectious Immunology Market Pipeline Products 187 Table 76: Microbiology Culture Market Pipeline Products 194 Table 77: Histology And Cytology Market Pipeline Products 195 Table 78: Genetic Testing Market Pipeline Products 196 Table 79: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 201 Table 80: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments For Archimedes Particle Metrology System 203 Table 81: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 204 Table 82: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New Oncology Assays 205 Table 83: Foundation Medicine Enters Into Agreement With Eisai For Genomic Profiling And Diagnostic Discovery 206
- 12. Table 84: Med BioGene Amends Licensing Agreement With Precision Therapeutics For LungExpress Dx Test 207 Table 85: Ovizio Imaging Systems Enters Into Distribution Agreement With Applikon Biotechnology 209 Table 86: CML HealthCare Enters Into Agreement With MaRS Innovation 210 Table 87: Akrivis Technologies Enters Into Co-Development Agreement With United States Biological 211 Table 88: Castle Biosciences Enters Into Licensing Agreement With Brigham and Women''s Hospital For Mesothelioma Test 212 Table 89: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For Protein Array Products 213 Table 90: GeneCentric Diagnostics Enters Into Licensing Agreement With University of North Carolina 214 Table 91: Dolomite Centre Enters Into Licensing Agreement With Japan Science and Technology Agency For Microdroplet Generation Technology 215 Table 92: Epistem Enters Into Distribution Agreement With Becton Dickinson For Mycobacterium TB Test 216 Table 93: Siemens Healthcare Diagnostics Enters Into Distribution Agreement With Sysmex 217 Table 94: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich For PhenoFluor 218 Table 95: Sysmex Asia Pacific Enters Into Distribution Agreement With DiaSys Diagnostic Systems 219 Table 96: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 220 Table 97: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test 221 Table 98: Guided Therapeutics Extends Licensing And Co-Development Agreement With Konica Minolta 222 Table 99: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening For AdenoPlus 223 Table 100: Immuno-Biological Labs To Form Joint Venture With TransGenic 224 Table 101: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 225 Table 102: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4 POC Test 226 Table 103: One Lambda Enters Into Co-Marketing Agreement With CellTrend 227 Table 104: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight Genetics For ALK Cancer Biomarker 228 Table 105: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 229 Table 106: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG Marker 230 Table 107: Pacific Biosciences Enters Into Co-Marketing Agreement With Tomy Digital Biology 231 Table 108: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating Tumor
- 13. Cell Technology 232 Table 109: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 233 Table 110: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen For LongRange PCR Kit 234 Table 111: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 235 Table 112: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery For Pressure Cycling Technology 236 Table 113: Ezose Sciences Enters Into Co-Development Agreement With Hirosaki University For New Cancer Biomarkers 237 Table 114: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 238 Table 115: GE Healthcare Enters Into Co-Development Agreement With NXT2B For Compact Cyclotron And PET Tracer System 239 Table 116: Metabolon Enters Into Co-Development Agreement With Takeda Pharma 240 Table 117: GE Healthcare Enters Into Research Agreement With Clino 241 Table 118: NexDx Enters Into Licensing Agreement With University of California For Epigenetic Biomarkers 242 Table 119: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 243 Table 120: Molecular Response Enters Into Co-Marketing Agreement With Transparent 244 Table 121: Thermo Fisher Scientific Extends Licensing Agreement With Wako Pure Chemical Industries 245 1.2 List of Figures Figure 1: In Vitro Diagnostics, Market Segmentation 18 Figure 2: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, 2004-2018 19 Figure 3: In Vitro Diagnostics Market, Japan, Revenue Mix ($m), 2011 21 Figure 4: In Vitro Diagnostics Market, Japan, Category Contribution (%), 2011 22 Figure 5: In Vitro Diagnostics Market, Japan, Cross-Category Analysis, 2004-2018 23 Figure 6: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Historic, 2004-2011 25 Figure 7: In Vitro Diagnostics, Japan, Overall Revenue ($m), USD Constant, Forecast, 2011-2018 27 Figure 8: In Vitro Diagnostics, Japan, Company Share (%), 2011 29 Figure 9: Clinical Chemistry, Market Segmentation 31 Figure 10: Clinical Chemistry Market, Japan, Revenue Mix ($m), 2011 32 Figure 11: Clinical Chemistry Market, Japan, Segment Contribution (%), 2011 33 Figure 12: Clinical Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004- 2011 34 Figure 13: Clinical Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011- 2018 36 Figure 14: Clinical Chemisty Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 38 Figure 15: Clinical Chemisty Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment,
- 14. Forecast, 2011-2018 40 Figure 16: Urine Analysis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004- 2011 42 Figure 17: Urine Analysis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011- 2018 43 Figure 18: Clinical Chemistry, Japan, Company Share (%), 2011 45 Figure 19: Genetic Testing, Market Segmentation 47 Figure 20: Genetic Testing Market, Japan, Revenue Mix ($m), 2011 48 Figure 21: Genetic Testing Market, Japan, Segment Contribution (%), 2011 49 Figure 22: Genetic Testing, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004- 2011 50 Figure 23: Genetic Testing, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011- 2018 52 Figure 24: Genetic Testing, Japan, Company Share (%), 2011 55 Figure 25: Haematology Market, Market Segmentation 56 Figure 26: Haematology Market, Japan, Revenue Mix ($m), 2011 57 Figure 27: Haematology Market, Japan, Segment Contribution (%), 2011 58 Figure 28: Haematology, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 59 Figure 29: Haematology, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 61 Figure 30: Haematology Reagents, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 63 Figure 31: Haematology Reagents, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 65 Figure 32: Immunohaematology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 67 Figure 33: Immunohaematology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 69 Figure 34: Haemostasis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004- 2011 71 Figure 35: Haemostasis, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011- 2018 73 Figure 36: Haematology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 75 Figure 37: Haematology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 77 Figure 38: Haematology Cell Counters, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 79 Figure 39: Haematology Cell Counters, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 81 Figure 40: Haematology, Japan, Company Share (%), 2011 84
- 15. Figure 41: Histology and Cytology Market, Market Segmentation 86 Figure 42: Histology And Cytology Market, Japan, Revenue Mix ($m), 2011 87 Figure 43: Histology And Cytology Market, Japan, Segment Contribution (%), 2011 88 Figure 44: Histology And Cytology, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 89 Figure 45: Histology And Cytology, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 91 Figure 46: Histology And Cytology, Japan, Company Share (%), 2011 94 Figure 47: Immuno Chemistry Market, Japan, Revenue Mix ($m), 2011 96 Figure 48: Immuno Chemistry Market, Japan, Segment Contribution (%), 2011 97 Figure 49: Immuno Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004- 2011 99 Figure 50: Immuno Chemistry, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011- 2018 101 Figure 51: Disease Specific Immunochemistry, Japan, Revenue ($m) USD Constant, by Sub- Segment, Historic, 2004-2011 103 Figure 52: Disease Specific Immunochemistry, Japan, Revenue ($m) USD Constant, by Sub- Segment, Forecast, 2011-2018 105 Figure 53: Drugs of Abuse / Toxicology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 107 Figure 54: Drugs of Abuse / Toxicology, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 109 Figure 55: Endocrinology Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 111 Figure 56: Endocrinology Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 113 Figure 57: Immunochemistry Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 115 Figure 58: Immunochemistry Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 117 Figure 59: Therapeutic Drug Monitoring, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 119 Figure 60: Therapeutic Drug Monitoring, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 121 Figure 61: Immunochemistry Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 123 Figure 62: Immunochemistry Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 125 Figure 63: Immuno Chemistry, Japan, Company Share (%), 2011 128 Figure 64: Infectious Immunology, Market Segmentation 130 Figure 65: Infectious Immunology Market, Japan, Revenue Mix ($m), 2011 131 Figure 66: Infectious Immunology Market, Japan, Segment Contribution (%), 2011 132
- 16. Figure 67: Infectious Immunology, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 133 Figure 68: Infectious Immunology, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 135 Figure 69: Infectious Immunology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub- Segment, Historic, 2004-2011 137 Figure 70: Infectious Immunology Rapid Tests, Japan, Revenue ($m) USD Constant, by Sub- Segment, Forecast, 2011-2018 139 Figure 71: Infectious Immunology, Japan, Company Share (%), 2011 142 Figure 72: Microbiology Culture, Market Segmentation 144 Figure 73: Microbiology Culture Market, Japan, Revenue Mix ($m), 2011 145 Figure 74: Microbiology Culture Market, Japan, Segment Contribution (%), 2011 146 Figure 75: Microbiology Culture, Japan, Revenue ($m) USD Constant, by Segment, Historic, 2004-2011 147 Figure 76: Microbiology Culture, Japan, Revenue ($m) USD Constant, by Segment, Forecast, 2011-2018 149 Figure 77: Microbiology Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 151 Figure 78: Microbiology Analyzers, Japan, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 153 Figure 79: Microbiology Culture, Japan, Company Share (%), 2011 156 Figure 80: F. Hoffmann-La Roche Ltd., Company Share (%),Japan In Vitro Dia Contact: sales@reportsandreports.com for more information.